Research
Hormonal
Poor fetal and infant nutrition (low birth weight) increases the risk of developing Type 2 diabetes in adulthood, likely through programmed insulin resistance and beta-cell dysfunction.
For expectant mothers, maintaining good nutrition and managing blood sugar (if diabetic) is important for the child's long-term metabolic health. For adults with low birth weight, being aware of the increased risk for insulin resistance is prudent.
GoodSupportsHIGH confidence
The thrifty phenotype hypothesis states that poor nutrition in fetal and infant life is detrimental to the development and function of the beta-cells and insulin sensitive tissues, leading to insulin resistance under the stress of obesity.
Why this rating
Supported by multiple cohort studies (Sweden, US, Pima Indians) cited in the text.
Source
Emerging epidemic of type 2 diabetes in youth.
Arlan L. Rosenbloom et al. · Diabetes Care · 1999
DOI 10.2337/diacare.22.2.345
narrative_reviewCited 1,027×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Type 2 diabetes incidence in youth is increasing rapidly and is strongly associated with obesity, particularly in minority populations (Native American, African-American, Mexican-American, Japanese).Strong
- African-American youth exhibit greater insulin responses during glucose tolerance testing and hyperglycemic clamp studies compared to white youth, indicating reduced insulin sensitivity.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →